Sarcoidosis is a rare disease with the number of patients in the European Union (28
member states), Norway, Iceland and Lichtenstein estimated as∼ 102 000 [1, 2]. Some 40 …

Most cases of sarcoidosis are mild and self-limited, with a spontaneous cure. However, in
some patients, this disease may also be life-threatening, particularly when severe …

Sarcoidosis is a systemic inflammatory disease, characterised by granuloma formation upon
an unknown trigger in genetically predisposed individuals. The inflammation is …

Background: Patients suffering from sarcoidosis may present with a wide range of
symptoms. The aim of this study was to make an inventory of the clinical presentation of the …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Sarcoidosis is a chronic granulomatous inflammatory disorder of unknown origin with
heterogeneous outcome. In most cases the disease is self-limited, others progress or die …

Sarcoidosis is a multisystem granulomatous disease, associated with significant morbidity
and impaired quality of life. Treatment is aimed at recovering organ function, reducing …

Sarcoidosis is a systemic, granulomatous disease that can affect multiple organs and has a
variable clinical course. Corticosteroids (eg prednisone) remain the mainstay of therapy in …

There is a growing focus in patient perspectives in terms of sarcoidosis treatment. A
multidisciplinary approach including psychological support and attention to fatigue, may …

Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology. It
affects the lungs in over 90% of patients yet extra-pulmonary and multi-organ involvement is …